The emergence of new anticoagulation medications to treat nonvalvular atrial fibrillation and reduce stroke risk has been mostly welcomed by the medical community. But identifying patients who will receive the most benefit from a particular drug remains a challenge, and wider use may be limited until bleeding risks and other concerns associated with the drugs are better understood.
The prevalence of atrial fibrillation, which can cause blood clotting, continues to increase in the United States, with 1 in 4 individuals now being projected to develop the condition in his or her lifetime. Patients with atrial fibrillation have 5 times greater risk of stroke and are estimated to constitute 15% of all stroke victims and 30% of those whose strokes occur after age 80 years.
Graphic Jump Location
Patient selection and risk benefit analysis are keys for determining which anticoagulation medications physicians should prescribe to reduce stroke risk from atrial fibrillation.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.